Metastatic Progression and Tumour Heterogeneity
| Metastatic Progression and Tumour Heterogeneity |
| Autore | Hollande Fred |
| Pubbl/distr/stampa | Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 |
| Descrizione fisica | 1 online resource (312 p.) |
| Soggetto topico | Medicine and Nursing |
| Soggetto non controllato |
3D cultures
acidosis ADH angiocrine factor beta-catenin paradox biomechanics breast cancer carbonic anhydrase cell fate cellular heterogeneity circulating tumor cells circulating tumor cells (CTCs) clear cell renal cell carcinoma clonality collective and single-cell migration colon cancer colorectal cancer CTC-clusters DCIS deficient mismatch repair EMT endometrial carcinoma epigenetics epithelial mesenchymal plasticity epithelial-to-mesenchymal transition esophageal squamous cell carcinoma extracellular vesicles gene expression genomics heterogeneity hybrid E/M hyperpolarized 13C MRI immune checkpoints immune microenvironment immunotherapy interstitial pH intra-tumour heterogeneity intratumor heterogeneity lactic acid magnetic resonance imaging mammary gland metaplastic carcinoma metastasis metastatic niche microsatellite instability miRNA expression multisite tumor sampling mutation natural killer cells nuclear medicine organoids pancreatic cancer PET phenotypic plasticity PI3K/AKT pathway plasticity positron emission tomography precision medicine radiomics radiopharmaceuticals review signaling single-cell analysis single-cell RNAseq subclonal diversity SUV target discovery targeted therapy TP53 treatment resistance tumor ecology tumor endothelial cell tumor evolution tumor heterogeneity tumor microenvironment tumor mutation burden uterine carcinosarcoma Wnt signaling |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557105803321 |
Hollande Fred
|
||
| Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2020 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Updates on Molecular Targeted Therapies for CNS Tumors
| Updates on Molecular Targeted Therapies for CNS Tumors |
| Pubbl/distr/stampa | MDPI - Multidisciplinary Digital Publishing Institute, 2023 |
| Descrizione fisica | 1 online resource (368 p.) |
| Soggetto topico |
Medicine and Nursing
Oncology |
| Soggetto non controllato |
A172
A2AAR antagonist adenosine adenosine receptors antigen processing and presentation antioxidant apoptosis ATRX bevacizumab biomarker blood-brain barrier brain metastasis brain tumor cancer metabolism cell cycle arrest central nervous system chemotherapy CNS disease CNS lymphoma CpG island diffuse midline gliomas DNMT EGFR ependymoma EPHB2 epidermal growth factor receptor ERK/MAPK pathway FGFR3 G-CIMP GBM germline mutation glioblastoma glioblastoma molecular classification glioma Group A Group B H3K27M histone acetylation IDH-mutant glioma immune evasion immune score immunotherapy intraparenchymal metastases intrathecal isotope labeling KIF11 leptomeningeal low grade glioma low-grade glioma LPS lung cancer lung carcinoma lung malignancy mass spectrometry meningitis MET metastatic disease Metformin methotrexate methylation methylomics methyltransferases MGMT molecular targets molecular therapy monoclonal antibodies MYCN myxopapillary n/a neoantigen neoplastic neurofibromatosis NF1 novel therapeutics novel therapies patient avatars PCNSL PDGFRA pediatric brain tumor PFA PFB PI3K/PTEN pathway plexiform neurofibroma potential therapy development preclinical models progression progression-free survival radiotherapy receptor tyrosine kinase RELA stereotactic radiosurgery subependymoma T cells T lymphocytes targeted therapy temozolomide tumor microenvironment tumor mutation burden tumor suppressor tyrosine kinase inhibitors U87MG vestibular schwannoma Warburg effect whole-brain radiation therapy YAP1 ZFTA |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9911053032003321 |
| MDPI - Multidisciplinary Digital Publishing Institute, 2023 | ||
| Lo trovi qui: Univ. Federico II | ||
| ||